Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:11:06 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:RDHL - REDHILL BIOPHARMA LTD SPON ADR EACH REP 10000 ORD SHS (P/S) - https://www.redhillbio.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RDHL - Q0.10.9055·1.470.11.07+0.043.937.2361081.05  1.1114  1.035.8646  0.90519:24:20Jan 0515 min RT 2¢

Recent Trades - Last 10 of 108
Time ETExPriceChangeVolume
19:24:20Q1.120.091,000
18:12:26Q1.11990.08991,200
17:46:02Q1.120.091,161
16:10:04Q1.070.041
16:04:07Q1.070.041
16:00:00Q1.070.04438
16:00:00Q1.070.0498
15:59:08Q1.100.0711
15:57:46Q1.070.04286
15:55:09Q1.090.0610

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-05 07:00U:RDHLNews ReleaseRedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
2025-12-15 07:00U:RDHLNews ReleaseRedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
2025-12-01 07:00U:RDHLNews ReleaseRedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
2025-11-04 09:30U:RDHLNews ReleaseRedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
2025-10-22 16:50U:RDHLNews ReleaseRedHill Biopharma Receives Nasdaq Staff Determination Notification
2025-10-20 09:05U:RDHLNews ReleaseCUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
2025-10-20 09:00U:RDHLNews ReleaseRedHill's Talicia(TM) Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
2025-10-06 08:00U:RDHLNews ReleaseRedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia(TM)
2025-09-29 07:00U:RDHLNews ReleaseRedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo
2025-09-05 07:00U:RDHLNews ReleaseRedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights
2025-08-20 09:00U:RDHLNews ReleaseRedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win
2025-08-18 09:00U:RDHLNews ReleaseRedHill Received Talicia(TM) Licensing Payments Totaling $1.1 Million
2025-07-21 09:00U:RDHLNews ReleaseRedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease
2025-07-01 12:00U:RDHLNews ReleaseRedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer
2025-05-13 07:00U:RDHLNews ReleaseRedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win
2025-05-02 07:00U:RDHLNews ReleaseRedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress
2025-04-28 07:03U:RDHLNews ReleaseRedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107
2025-04-17 16:01U:RDHLNews ReleaseRedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
2025-04-16 07:00U:RDHLNews ReleaseRedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption
2025-04-10 07:48U:RDHLNews ReleaseRedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights